Pages: 2412-2415
Year: 2017 Issue:  15
Journal: Journal of Modern Oncology
Abstract: Objective:To observation of efficacy and toxicity of spleen polypeptide and docetaxel plus cisplation in treatment of advanced non-small cell lung cancer(NSCLC).Methods:The 60 cases of NSCLC patients were randomly into 2 groups,which were spleen peptide group(30 cases)and control group(30 cases).The spleen peptide group was given spleen peptide jointly with docetaxel plus cisplation and the control group with docetaxel plus cisplation.The spleen peptide group was treated with the spleen peptide 6mg/d intravenously from the beginning of combination therapy,1 week.The patients were detected with blood(including peripheral blood leukocytes,platelets,hemoglobin),liver and kidney function,gastrointestinal reactions,immune functions testing in order to survive score and treatment evaluation before and after chemotheraphy.Results:The total effective rate were 46.7% and 43.3% in the spleen peptide group and the control group respectively.The degree of reduction of white blood cells, platelets and hemoglobin in the spleen peptide group was better than that in the control group.The percentage of positive cells of immune parameters NK/T-cell CD4 positive cell and CD4/CD8 ratio were increase significantly.Conclusion:Spleen peptides combined with docetaxel plus cisplation may increase efficacy,reduce bone marrow toxicity,improve immunity,improve the quality of life and tolerability of chemotherapy in patients with advanced non-small cell lung cancer.The therapy was worthy of promotion.